316 related articles for article (PubMed ID: 22180804)
1. Risk factors for ocular chlamydia after three mass azithromycin distributions.
Ayele B; Gebre T; Moncada J; House JI; Stoller NE; Zhou Z; Porco TC; Gaynor BD; Emerson PM; Schachter J; Keenan JD
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1441. PubMed ID: 22180804
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.
Keenan JD; See CW; Moncada J; Ayele B; Gebre T; Stoller NE; McCulloch CE; Porco TC; Gaynor BD; Emerson PM; Schachter J; Lietman TM
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):235-40. PubMed ID: 22159017
[TBL] [Abstract][Full Text] [Related]
3. A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.
Morberg DP; Alemayehu W; Melese M; Lakew T; Sisay A; Zhou Z; Cevallos V; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
Ophthalmic Epidemiol; 2019 Feb; 26(1):19-26. PubMed ID: 30153085
[TBL] [Abstract][Full Text] [Related]
4. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.
Keenan JD; Ayele B; Gebre T; Moncada J; Stoller NE; Zhou Z; Porco TC; McCulloch CE; Gaynor BD; Emerson PM; Schachter J; Lietman TM
Clin Infect Dis; 2012 Jan; 54(2):253-6. PubMed ID: 22095569
[TBL] [Abstract][Full Text] [Related]
5. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
[TBL] [Abstract][Full Text] [Related]
6. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
[No Abstract] [Full Text] [Related]
7. Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.
Kim JS; Oldenburg CE; Cooley G; Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Keenan JD; Gaynor BD; Porco TC; Lietman TM; Martin DL
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007127. PubMed ID: 30689671
[TBL] [Abstract][Full Text] [Related]
8. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
Biebesheimer JB; House J; Hong KC; Lakew T; Alemayehu W; Zhou Z; Moncada J; Rogér A; Keenan J; Gaynor BD; Schachter J; Lietman TM
Ophthalmology; 2009 Nov; 116(11):2047-50. PubMed ID: 19744717
[TBL] [Abstract][Full Text] [Related]
9. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial.
Amza A; Kadri B; Nassirou B; Stoller NE; Yu SN; Zhou Z; Chin S; West SK; Bailey RL; Mabey DC; Keenan JD; Porco TC; Lietman TM; Gaynor BD;
PLoS Negl Trop Dis; 2012; 6(4):e1586. PubMed ID: 22545165
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.
Edwards T; Harding-Esch EM; Hailu G; Andreason A; Mabey DC; Todd J; Cumberland P
Trop Med Int Health; 2008 Apr; 13(4):556-65. PubMed ID: 18282237
[TBL] [Abstract][Full Text] [Related]
11. Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial.
Arzika AM; Mindo-Panusis D; Abdou A; Kadri B; Nassirou B; Maliki R; Alsoudi AF; Zhang T; Cotter SY; Lebas E; O'Brien KS; Callahan EK; Bailey RL; West SK; Goodhew EB; Martin DL; Arnold BF; Porco TC; Lietman TM; Keenan JD;
JAMA Netw Open; 2022 Aug; 5(8):e2228244. PubMed ID: 35997979
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities.
Wilson N; Goodhew B; Mkocha H; Joseph K; Bandea C; Black C; Igietseme J; Munoz B; West SK; Lammie P; Kasubi M; Martin DL
Ophthalmic Epidemiol; 2019 Feb; 26(1):1-6. PubMed ID: 30543311
[TBL] [Abstract][Full Text] [Related]
13. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
[TBL] [Abstract][Full Text] [Related]
14. Frequency of Mass Azithromycin Distribution for Ocular Chlamydia in a Trachoma Endemic Region of Ethiopia: A Cluster Randomized Trial.
Lietman TM; Ayele B; Gebre T; Zerihun M; Tadesse Z; Emerson PM; Nash SD; Porco TC; Keenan JD; Oldenburg CE
Am J Ophthalmol; 2020 Jun; 214():143-150. PubMed ID: 32171768
[TBL] [Abstract][Full Text] [Related]
15. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
[TBL] [Abstract][Full Text] [Related]
16. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
[TBL] [Abstract][Full Text] [Related]
17. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
[TBL] [Abstract][Full Text] [Related]
18. Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II).
Mahmud H; Haile BA; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Liu Z; Callahan EK; Cotter SY; Varnado NE; Oldenburg CE; Porco TC; Lietman TM; Keenan JD
Clin Infect Dis; 2023 Aug; 77(3):388-395. PubMed ID: 37021692
[TBL] [Abstract][Full Text] [Related]
19. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.
Porco TC; Gebre T; Ayele B; House J; Keenan J; Zhou Z; Hong KC; Stoller N; Ray KJ; Emerson P; Gaynor BD; Lietman TM
JAMA; 2009 Sep; 302(9):962-8. PubMed ID: 19724043
[TBL] [Abstract][Full Text] [Related]
20. The conjunctival microbiome before and after azithromycin mass drug administration for trachoma control in a cohort of Tanzanian children.
Pickering H; Ramadhani AM; Massae P; Mafuru E; Malisa A; Mbuya K; Makupa W; Mtuy T; Derrick T; Houghton J; Bailey RL; Mabey DCW; Burton MJ; Holland MJ
Front Public Health; 2022; 10():1015714. PubMed ID: 36324475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
